ABPI - OHE

We found for

Optimise_AdobeStock_576507456_landscape

Insight
April 2023

How Restrictive are NICE ‘Optimised’ Decisions?

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism

Read more

Sustainability

Supporting the Era of Green Pharmaceuticals in the UK

Read more

Insight
June 2021

Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?

Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?

Read more

The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective

Read more

Health Technology Assessment…

Realising the Broader Value of Vaccines in the UK

Read more

NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?

Read more

Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies

Read more

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Read more

Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

Read more

Public Preferences for Health Gains and Cures: A Discrete Choice Experiment

Read more

Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS

Read more

The Impact of New Medicines in the NHS: 70 Years of Innovation

Read more

Issues Surrounding the Estimation of the Opportunity Cost of Adopting a New Health Care Technology: Areas for Further Research

Read more

Establishing a Reasonable Price for an Orphan Drug

Read more